CAMP4 receives UK authorization for its first SYNGAP1 clinical study

CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, while European Union submissions remain under review. The company expects to begin first-in-human dosing in the fourth quarter of 2026.

CMP002 is an antisense-oligonucleotide candidate designed to act on regulatory RNA and increase production of the relevant protein. The upcoming study will begin testing the approach in patients rather than establishing commercial access to a finished therapy. Regulatory permission to conduct a trial does not demonstrate clinical benefit, and the company has not reported human efficacy results from this program in the announcement. The milestone expands the geographic base for the planned study.

Sources:

• CAMP4 — UK study authorization